欧普康视：取得《药品生产许可证》

Core Viewpoint - The company has recently obtained a "Drug Manufacturing License" from the Anhui Provincial Drug Administration, marking its first acquisition of such a license, which is expected to positively influence the company's long-term development [1] Group 1 - The acquisition of the "Drug Manufacturing License" will help optimize the company's product structure [1] - The company still needs to complete regulatory procedures, including product registration application, on-site verification, and compliance checks with GMP, before obtaining the "Drug Registration Certificate" for commercial production and sales [1] - The short-term impact of the "Drug Manufacturing License" on the company's operating performance is expected to be minimal [1]